EPGNY实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (22 Sep 2022 @ 02:34):

Stats
今日成交量	212.00
平均成交量	9.00
市值	0.00
Last Dividend	$0.0297 ( 2021-09-16 )
Next Dividend	$0 ( N/A )
P/E	-1.604
ATR14	$0 (0.00%)

Epigenomics AG 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Epigenomics AG 财务报表

Annual	2021
营收:	$6.20M
毛利润:	$6.07M (97.81 %)
EPS:	$-0.271

FY	2021
营收:	$6.20M
毛利润:	$6.07M (97.81 %)
EPS:	$-0.271

FY	2020
营收:	$842 000
毛利润:	$697 000 (82.78 %)
EPS:	$-2.48

FY	2019
营收:	$1.13M
毛利润:	$872 000 (77.51 %)
EPS:	$-4.48

Financial Reports:

No articles found.

Epigenomics AG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Epigenomics AG Dividend Information - No Dividend Player

Dividend Sustainability Score: 0.458 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.833	2018-10-31
Last Dividend	$0.0297	2021-09-16
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	$2.72	--
Avg. Dividend % Per Year	0.00%	--
Score	0.55	--
Div. Sustainability Score	0.458
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-09-23)

$0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

0.55

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
NWYF	Ex Dividend Junior	2023-08-04	Semi-Annually	0.00%
CRRFY	Ex Dividend Junior	2023-06-06	Sporadic	0.00%
TSGTY	Ex Dividend Knight	2023-06-23	Annually	0.00%
IHICF	No Dividend Player	2023-09-28	Annually	0.00%
AUOTY	No Dividend Player	2023-08-10	Sporadic	0.00%
PTBS	Ex Dividend Knight	2023-08-03	Quarterly	0.00%
EBKDY	Ex Dividend Junior	2023-05-16	Annually	0.00%
VWAGY	Ex Dividend Junior	2023-05-11	Annually	0.00%
KIGRY	Ex Dividend Junior	2023-05-18	Annually	0.00%
BSPA	Ex Dividend Knight	2023-09-01	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.391	1.500	-7.83	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.0984	1.200	-3.28	-3.94	[0 - 0.3]
returnOnEquityTTM	-0.187	1.500	-3.19	-4.78	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	11.06	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	10.72	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	10.72	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0187	-1.500	9.69	-10.00	[0 - 0.6]
interestCoverageTTM	-45.35	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.463	2.00	-0.154	-0.309	[0 - 30]
freeCashFlowPerShareTTM	-0.467	2.00	-0.233	-0.467	[0 - 20]
debtEquityRatioTTM	0.0208	-1.500	9.92	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.978	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-0.380	1.000	-9.60	-9.60	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-9.03	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.252	0.800	-1.657	-1.325	[0.5 - 2]
Total Score				0.458

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-8.20	1.000	-0.929	0	[1 - 100]
returnOnEquityTTM	-0.187	2.50	-2.05	-4.78	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.467	2.00	-0.156	-0.467	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.463	2.00	-0.154	-0.309	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.463	1.500	-6.42	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.669	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.63

Epigenomics AG

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.